Tyrosine kinase inhibitors (TKIs) represent the successful molecular therapy for patients with chronic myeloid leukemia (CML), nevertheless several mechanisms have been associated with resistance to TKIs, including the presence of rare quiescent leukemic stem cells, less susceptible to TKIs. Moreover, Bcr-Abl activates additional signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5 pathways, potentially contributing to CML TKIs drug resistance . Therefore, in this study we aimed to investigate, at the protein level, proliferative and apoptotic STP in CML CD34+ cells as compared to normal CD34+ cells in order to identify additional aberrant signals potentially therapeutic targetable. CD34+ cells were purified from peripheral blood (PB) of seven newly diagnosed chronic phase (CP) CML patients and one normal bone marrow (nBM). The phosphorylation status of 46 proteins from various STP and the expression of 32 proteins of the apoptotic machinery were assessed by
Proteomic signature of CD34+ progenitors from chronic-phase chronic myeloid leukemia / Ricciardi, Maria Rosaria; V., Salvestrini; M., Forcato; Licchetta, Roberto; Mirabilii, Simone; L., Rossi; Allegretti, Matteo; S., Salati; F., Castagnetti; G., Rosti; G., Alimena; R., Manfredini; S., Bicciato; R. M., Lemoli; Tafuri, Agostino. - In: HAEMATOLOGICA. - ISSN 0390-6078. - ELETTRONICO. - (2013). (Intervento presentato al convegno 44° Congresso Nazionale SIE tenutosi a Verona nel 20-23 Ottobre 2013).
Proteomic signature of CD34+ progenitors from chronic-phase chronic myeloid leukemia
RICCIARDI, Maria Rosaria;LICCHETTA, ROBERTO;MIRABILII, SIMONE;ALLEGRETTI, MATTEO;TAFURI, Agostino
2013
Abstract
Tyrosine kinase inhibitors (TKIs) represent the successful molecular therapy for patients with chronic myeloid leukemia (CML), nevertheless several mechanisms have been associated with resistance to TKIs, including the presence of rare quiescent leukemic stem cells, less susceptible to TKIs. Moreover, Bcr-Abl activates additional signal transduction pathways (STP), such as RAS/MEK/ERK, PI3K/Akt, Wnt and STAT5 pathways, potentially contributing to CML TKIs drug resistance . Therefore, in this study we aimed to investigate, at the protein level, proliferative and apoptotic STP in CML CD34+ cells as compared to normal CD34+ cells in order to identify additional aberrant signals potentially therapeutic targetable. CD34+ cells were purified from peripheral blood (PB) of seven newly diagnosed chronic phase (CP) CML patients and one normal bone marrow (nBM). The phosphorylation status of 46 proteins from various STP and the expression of 32 proteins of the apoptotic machinery were assessed byI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
